NCT03506412View on ClinicalTrials.gov

Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 25, 2018

Primary Completion Date

March 23, 2021

Study Completion Date

March 23, 2021

Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
DRUG

Entresto™ 49Mg-51 mg tablet

Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Mayo Clinic

OTHER

NCT03506412 - Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction | Biotech Hunter | Biotech Hunter